Becton, Dickinson and Company (NYSE:BDX) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Becton, Dickinson and Company (NYSE:BDX) have been given a consensus rating of “Hold” by the seventeen research firms that are currently covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $187.67.

BDX has been the topic of several research reports. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. TD Cowen boosted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a report on Friday, August 7th.

Becton, Dickinson and Company Trading Down 0.6%

Becton, Dickinson and Company stock opened at $178.00 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The business’s fifty day simple moving average is $180.28 and its two-hundred day simple moving average is $161.60. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07. The company has a market capitalization of $49.05 billion, a price-to-earnings ratio of 53.61, a price-to-earnings-growth ratio of 12.62 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,906 shares of company stock valued at $1,265,855 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth $26,000. Meeder Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the last quarter. Main Street Group LTD purchased a new stake in Becton, Dickinson and Company in the 1st quarter worth $29,000. Bell Investment Advisors Inc bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $29,000. Finally, Kelleher Financial Advisors purchased a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $30,000. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.